Avanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.

Avanos Medical, Inc.

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Don Baxter

Ralph Falk

Thomas Stallkamp

Baxter International Inc.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Maxwell Becton

Fairleigh Dickinson

Becton, Dickinson and Company

Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, it operated 4,171 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.

Eduard Fresenius

Fresenius Medical Care AG & Co. KGaA

Avanos Medical is a medical device company dedicated to challenging the status quo in healthcare. Its solutions focus on pain management, respiratory care, and digestive care.

Metric
Company Name	Avanos Medical, Inc.	Baxter International Inc.	Becton, Dickinson and Company	Fresenius Medical Care AG & Co. KGaA
Symbol	AVNS	BAX	BDX	FME
MSH ID	COM:AVANOS	COM:BAXTER	COM:BD	COM:FRESENIUSMEDICALCARE
Market	STOCKS	STOCKS	STOCKS	STOCKS
Sector	Healthcare	Healthcare	Healthcare	Healthcare
Industry	Medical - Devices	Medical - Instruments & Supplies	Medical - Instruments & Supplies	Medical - Care Facilities
Country	US	US	US	DE
Stage
Employee Count	3.77K	60K	70K	117.13K
Website	avanos.com	baxter.com	bd.com	freseniusmedicalcare.com
LinkedIn			bd1	fresenius-medical-care-italia-spa
Founders

Metric
Market Cap	890.08M	17.45B	64.70B	11.22B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	673.30M	14.81B	20.18B	20.55B
Revenue (LTM)
Revenue (NTM)
Gross Profit	382.70M	4.97B	20.18B	5.20B
EBITDA	98.50M	1.75B	2.42B	3.63B
Operating Income	52.40M	390M	2.42B	1.58B
Net Income	-61.80M	2.66B	1.73B	527.06M
EPS	-1.33	5.25	5.96	1.80
Diluted EPS	-1.33	5.25	5.93	1.80
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.57	0.36	0.55	0.25
Operating Profit Margin	0.07	0.06	0.12	0.08
EBITDA Margin	0.15	0.12	0.12	0.18
Net Profit Margin	0.02	0.18	0.07	0.03
Return on Equity	0.01	0.38	0.06	0.04
Return on Assets	0.01	0.10	0.03	0.02
Return on Capital Employed	0.03	0.05	0.05	0.06

COM:AVANOS

Avanos Medical

Last Close

18.02

22/11 21:00

Market Cap

890.08M

Beta: -

Volume Today

347.33K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-15.55	7.55	54.49	19.14
P/B Ratio	0.71	2.41	2.70	0.75
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	1.66	1.42	3.63	0.63
EV Multiple	13.78	8.56	15.21	0.95

Metric
Days Sales Outstanding	70.67	61.33	42.45	69.66
Days Payables Outstanding	56.73	45.88		21.21
Days Inventory Outstanding	205.17	113.15	105.52	56.09
Operating Cycle	275.64	178.17	151.20	132.45
Cash Conversion Cycle	205.02	130.96	47.37	112.72
Asset Turnover	0.42	0.57	0.37	0.62

Metric
Operating Cash Flow	32.40M	1.73B	3.84B	2.78B
Free Cash Flow	14.60M	1.03B	3.12B	2.05B
Cash Flow to Debt	0.33	0.12	0.21	0.34
Operating Cash Flow/Sales	0.09	0.12	0.20	0.16
Free Cash Flow Yield	0.04	0.05	0.04	0.16

Metric
Cash & Equivalents	87.70M	3.19B	1.86B	1.48B
Accounts Receivable	39M	-66M		-160.38M
Inventory	163.20M	2.82B	3.84B	2.30B
Goodwill	796.10M	6.51B	26.46B	15.47B
Debt to Capitalization	0.15	0.64	0.43	0.47
Debt to Assets	0.18	0.55	0.33	0.36
Current Ratio	3.07	1.94	1.08	1.37
Quick Ratio	1.49	1.01	1.36	1.14

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.02	0.01	0.01	-0.02
R&D to Revenue	0.04	0.04	0.06	0.01
SG&A to Revenue		0.06